IP Library Granted Patent US 9,155,698
Granted Patent B2
US 9,155,698 · App. 14/490,959 · Granted Oct 13, 2015

Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films

Inventor: Robert Steven Davidson (Woodland Hills, CA)
Assignee: CURE Pharmaceutical Corporation
A61K9/006A61K9/0051A61K9/0056A61K31/167A61K31/43A61K33/06A61K47/36A61K47/38A61K9/7007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,155,698
App. No.
14/490,959
Granted
Oct 13, 2015
Kind
B2
Abstract

A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.

Claims (25)

1. A method of delivering a medicant in the oral cavity of a mammal, comprising disposing within the oral cavity of the mammal a thin film composition comprising the medicant, the thin film composition being prepared by a method comprising the steps of:

providing a film layer comprising a water-soluble polymer selected from the group consisting of pullulan, modified starch, pectin, carrageenan, a maltrodextrin, and an alginate; or any combination thereof;

applying a coating to said film layer without use of a solvent, wherein said coating comprises a powder matrix;

wherein the powder matrix, prior to application to the film layer, is admixed in a fluidized bed that minimizes the generation of shear and heat;

wherein the powder matrix comprises a medicant;

the powder matrix further comprising a composition that, when placed in the oral cavity in contact with the mucosa therein, cases the thin film composition to adhere to the mucosa.

2. The method of claim 1 , wherein the powder matrix is applied to the film layer by use of a static spray gun using compressed air.

3. The method of claim 1 , wherein after placing the thin film composition within the oral cavity of the mammal, the thin film composition adheres to the mucosa of the oral cavity.

4. The method of claim 3 , wherein the film dissolves within the oral cavity in a period of less than about 15 seconds.

5. The method of claim 1 , wherein the thin film composition further comprises an auxiliary dissolution control composition that acts to slow the release of the medicant in the oral cavity.

6. The method of claim 5 , wherein the auxiliary dissolution control composition comprises carrageenan, gelatin, alginates, pullulan, cyclodextrin, calcium, or carboxymethylcellulose, or any combination thereof.

7. The method of claim 1 , wherein the thin film composition comprises an absorption composition that absorbs water or saliva.

8. The method of claim 7 , wherein the absorption composition comprises carboxymethylcellulose, pectin, a modified starch, gelatin, or carrageenan, or any combination thereof.

9. The method of claim 1 , wherein the thin film composition is formed by a curing process, wherein the thin film composition comprises a flow composition that upon heating of the thin film composition to a selected temperature about 76 degrees F. causes the flow composition to soften and flow to form a smoother or shinier coating on the exterior of the film compared to a film prepared by an analogous process but lacking the curing of the flow composition.

10. The method of claim 9 , wherein the flow compositions comprises a lipid, a wax, or a polyol, or any combination thereof.

11. The method of claim 1 , wherein the medicant is an anti-inflammatory steroid.

12. The method of claim 11 , wherein the steroid is predonisone, predonisolone, predonisolone acetate, hydrocortisone, triamcinolone, dexomethanose or betamethasone.

13. The method of claim 1 , wherein the medicant is an anti-inflammatory anodyne.

14. The method of claim 13 , wherein the anodyne is aspirin, aminopyrin, acetoaminophen, ibufenac, ibuprofen, indomethacin, colchicine, sulpyrine, mephenamic acid, phenacetin, phenylbutazone, fulfenamic aicd, or probenecid.

15. The method of claim 1 , wherein the medicant is an anti-histamine.

16. The method of claim 15 , wherein the anti-histamine is diphenhydramine or chlorpheniramine.

17. The method of claim 1 , wherein the medicant is an oral sterilizing agent.

18. The method of claim 17 , wherein the oral sterilizing agent is chlorohexydine-hydrochloride, cetylpyridinium-chloride, hexylresorcin, or nitro-furazone.

19. The method of claim 1 , wherein the medicant is an antibiotic.

20. The method of claim 19 , wherein the antibiotic is a penicillin, a cephalosporine, erythromycine, tetracycline, furadiomycin, or leucomycin.

Assignments (8)
LIEN Recorded Jan 28, 2025
From: CURE PHARMACEUTICAL, INC.
To: CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V.
Reel/Frame 070027/0201 →
CHANGE OF NAME Recorded Jul 17, 2023
From: TF TECH VENTURES, INC.
To: CURE PHARMACEUTICAL, INC.
Reel/Frame 064286/0450 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME WHICH SHOULD READ TF TECH VENTURES, INC. AND NOT TF TECH VENTURES PREVIOUSLY RECORDED AT REEL: 060598 FRAME: 0016. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 12, 2023
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES, INC.
Reel/Frame 064256/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2022
From: CURE PHARMACEUTICAL CORPORATION
To: TF TECH VENTURES
Reel/Frame 060598/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2022
From: CURE PHARMACEUTICAL HOLDING CORP.
To: CURE PHARMACEUTICAL CORPORATION
Reel/Frame 060516/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2020
From: CURE PHARMACEUTICAL CORPORATION
To: CURE PHARMACEUTICAL HOLDING CORP.
Reel/Frame 054445/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2019
From: INNOZEN, INC.
To: CURE PHARMACEUTICAL CORPORATION
Reel/Frame 049388/0512 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2019
From: DAVIDSON, ROBERT S.
To: INNOZEN, INC.
Reel/Frame 049384/0801 →
Continuity (3)
Division 11836758 · Aug 9, 2007
Division 10402273 · Mar 28, 2003
Related Publication 20150004216A1 · Jan 1, 2015